CEL-SCI Corporation Announces $6.0 Million Public Offering
Sichenzia Ross Friedman Ference LLP Represents CEL-SCI Corporation on $6.0 Million Public Offering
New York, NY – October 29, 2014 – GLOBAL NEWSWIRE – New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced that it has advised Laidlaw & Co. (UK) Ltd. as the Lead Underwriter in a $6 million public Public Offering of CEL-SCI Corporation (NYSE MKT: CVM), a late-stage biotechnology company focused on oncology research and drug development. The underwriting was pursuant to a prospectus supplement to an effective S-3 registration statement. The offering consisted of common stock and warrants at a combined price of $0.76 per unit. Pursuant to the offering, CEL-SCI issued one warrant to purchase common stock for every four shares sold. The warrants have an exercise price of $1.25 per unit. The Sichenzia Ross Friedman Ference LLP team was led by Partner Richard A. Friedman and Associate Stephen Cohen.
- Sichenzia Ross Ference to Sponsor Gravitas Securities 6th Annual Growth Conference - November 22, 2022
- Memorandum RE: Pay v. Performance Disclosure Rules - November 22, 2022
- The Wall Street Conference: Nobu Hotel in Miami Beach February 6-8 - November 17, 2022